During the last two decades, there has been great interest in the effects of administered hormones on the risk of cancer in women. Most attention has been focused on synthetic sex hormones given (1) during pregnancy to try to prevent abortion and late pregnancy toxaemia;
(2) at and after the menopause to relieve menopausal symptoms and to protect the skeleton; and (3) during the childbearing years to prevent pregnancy. This paper presents a brief overview of these three problem areas from the epidemiological standpoint, dealing in a summary way with what is established and in a little more detail with what is controversial. At the outset, it should be stressed that both animal experimental work (see International Agency for Research on Cancer 1979) and epidemiological, clinical and laboratory research on the effects of endogenous hormones in the human (see Henderson et al. 1982) have made it clear that some influence of administered female sex hormones on the risk of certain cancers would be anticipated; as we shall see, this has turned out to be the case.
Administration of hormones during pregnancy During the 1950s and 1960s, stilboestrol was administered to some 2-3 million pregnant women in the USA. The total dosage of the drug given during pregnancy was sometimes as high as 12 or even 15 g. Stilboestrol and closely-related drugs were also used extensively in this way in a number of other countries -Holland, for example. In the UK, it appears that fewer than 10000 pregnant women were involved (Kinlen et al. 1974) .
The object of therapy was to prevent abortion and late pregnancy toxaemia. However, clinical trials conducted during the l950s showed that not only did the treatment not work, it actually had a harmful effect on the outcome of pregnancy (Dieckmann et al. 1953 , Brackbill & Berendes 1978 , Vessey et al. 1983a ). This makes the long-term adverse effects of treatment which have emerged during the last 10 or 15 years all the more tragic.
In the daughters who were exposed in utero to stilboestrol, the most important such effect is, of course, the development of clear-cell adenocarcinoma of the vagina or cervix. Very few cases of this disease have been reported before puberty, but the cumulative risk thereafter up to the age of 24 years is estimated to be between 1.4 and 14 per 10000 exposed . The tumours probably arise in areas of vaginal or cervical adenosis which are much more common and much more extensive in young women exposed in utero to stilboestrol than in other women (Scully & Welch 1981) . These areas of adenosis gradually become replaced with metaplastic squamous epithelium during the teens and twenties, so there is good reason to hope that the risk of clear-cell cancer will diminish or even disappear with increasing age (Noller et al. 1983) . It is worth noting that at least three cases of stilboestrolassociated clear-cell cancer have been reported in the UK (Monaghan & Sirisena 1978 , Dewhurst et al. 1980 , Davis et al. 1981 . Fortunately, no other special cancer risk has yet been established for these unfortunate young women.
Much less attention has been paid to the mothers who actually took the stilboestrol than to their daughters. However, the published data do not provide any convincing evidence of an increased risk of either breast or reproductive cancer among them (Brian et al. 1980 , Beral & Colwell 1980 , Hubby et al. 1981 , Vessey et al. 1983a ). The results of further studies known to be in progress in the USA are awaited.
Although the 'stilboestrol story' is now largely over in that use of the drug during pregnancy ceased more than 10 years ago, the consequences of this medical mistake are still becoming apparent while, in the USA at least, large sums of money are being spent on surveillance of exposed subjects and litigation is in full swing. The question also arises as to whether adenosis or adenocarcinoma of the vagina or cervix might follow exposure in utero to progestogens or, more importantly, to oral contraceptives. The available data on this topic are very few but as far as they go they appear reassuring (Scully & Welch 1981) .
Administration of hormones around the time of the menopause Oestrogen replacement therapy is extremely effective in the relief of the vasomotor symptoms and genital atrophy which may occur around the time of the menopause and for preventing the development of postmenopausal osteoporosis. It may have other beneficial effects toofor example, on a woman's appearance and on her risk of coronary heart disease (Vessey & Bungay 1982) . However, as is well known, there are problems with this type of treatment which are relevant to the theme of this paper.
First, it is well established that unopposed oestrogen therapy in menopausal women can cause endometrial cancer. This has been demonstrated in a large number of case-control studies reported since 1975; I am aware of 18 and this is probably not the grand total . Most of these studies were conducted in the USA and most concern the drug Premarin (conjugated equine oestrogens). Some cohort studies have also been reported: by and large they have supported the results of the case-control studies, but the numbers of women with endometrial cancer have been small (Gambrell et al. 1979 , Persson 1983 , Hunt & Vessey 1984 . Some important features of the association between replacement therapy and endometrial cancer are (1) the risk is related to oestrogen dose and to duration of use;
(2) the risk declines after discontinuation of treatment; (3) cancers occurring in women using oestrogens tend to be less advanced at detection and of more favourable grade than cancers occurring in other womentheir prognosis is correspondingly more favourable; and (4) addition of a progestogen to the oestrogen during each 'cycle' of therapy may well reduce, eliminate or even reverse the risk (see Vessey & Bungay 1982) .
Secondly, there is also anxiety that replacement therapy may increase the risk of breast cancer, but this is a highly controversial area. I am aware of 7 recent case-control studies that have looked at this question (Table 1 ). All but one (Sherman et al. 1983 ) have provided some evidence that oestrogen therapy (again mostly with Premarin) carries an increase in breast cancer risk, but effects have, in general, been small. Nonetheless, some studies have shown a relationship between risk and dose of oestrogen and duration of use (Ross et al. 1980, Brinton et al. 1981 . A particular difficulty in these studies concerns the relationship between age at menopause, type of menopause and use of oestrogen therapy. Thus women with early oophorectomy are at low risk of breast cancer, but they are particularly likely to receive replacement therapy. It has been reasoned that any adverse effect of oestrogens on the breast might be particularly apparent in these women, eliminating the protection that might otherwise be expected from removal of the ovaries (Thomas 1982) . Table 1 shows the overall results of the 7 recent case-control studies, separating women with intact ovaries from those with the ovaries removed. The adverse effect of therapy on breast cancer risk (such as it is) is clearly not concentrated in those with oophorectomy.
There are also a few recent cohort studies which have looked at oestrogen therapy in relation to breast cancer risk (Hoover et al. 1976 , Gambrell et al. 1983 , Hunt & Vessey 1984 . The findings have been conflicting but have tended to support the idea that there is some adverse effect. The study by Gambrell et al. (1983) provides preliminary evidence that the addition of a progestogen to the oestrogen may reduce the hazard to the breast as well as to the endometrium.
In view of the potential importance of replacement therapy in the menopause, which in my view has been underrated by doctors and the public alike, it is to be hoped that the breast cancer question will be resolved. Sadly, if this is to be done by the case-control approach, it will not be possible to provide the answers in the UK because replacement therapy is little used here (Hunt & Vessey 1984) .
Administration of hormones to prevent pregnancy
Oral contraceptives first became available in the USA in 1959 and since that time they have been widely adopted by women in many different countries. Well over 50 million women worldwide are currently 'on the pill', while many millions more have used oral contraceptives in the past. Accordingly, a proper assessment of the possible relationship between oral contraceptive use and cancer is of great public health importance.
In this section, attention is concentrated on combined oral contraceptives. Reliable human data on progestogen-only pills and on injectable progestogen contraceptives are sparse and these preparations are not discussed here.
Ovarian cancer and endometrial cancer
There is now little doubt that combined oral contraceptives protect against both epithelial ovarian cancer and endometrial cancer. The overall results of the published case-control studies are summarized in Tables 2 and 3. It may be noted that the preliminary findings in the major cohort studies concerned with the long-term effects of oral contraceptive use are also encouraging (see . Both ovarian cancer and endometrial cancer are, however, rare below the age of 40 years, while present teaching about oral contraceptive use recommends discontinuation of medication in the majority of women at about 35 years of age because of the risk of cardiovascular adverse effects. Accordingly, for the protective effect of combined pills against ovarian and endometrial cancers to be of any real practical value, it must persist in ex-users, and persist for many years. The available data on this point look encouraging, but more information is needed (Vessey 1983 ).
Breast cancer
Turning now to breast cancer, the first point to be made is that a series of large case-control studies conducted during the 1970s showed quite clearly that there is no general association between oral contraceptive use and breast cancer risk (see Kalache et al. 1983 ). However, these large studies included few women with appreciable oral contraceptive use at an early age and accordingly the publication by Pike et al. in 1981 of the data shown in Table 4 caused considerable concern. Pike's study involved 163 women in Los Angeles County in whom breast cancer had been diagnosed at age 32 years or less, together with a like number of neighbourhood controls. and the Centers for Disease Control (1983a) subsequently published limited results which did not support the Californian findings. In October 1983, however, Pike et al. published a further report from Los Angeles. Their series of cases now included 314 women with breast cancer aged 36 years or less and their primary analyses concerned oral contraceptive use before age 25 years rather than before first-term pregnancy. Their main findings, which are clearly extremely worrying, are summarized in Table 5 . Pike et al. (1983) also related breast cancer risk in their study to the 'progestogen potency' of the oral contraceptives used as measured by the delay in menses test, claiming that the adverse effect was largely attributable to pills with a 'potency score' of 5 or more. Subsequent discussion about the paper by Pike et al. (e.g. Swyer 1983 , 1984 has made it clear that the classification of progestogen potency used by the Los Angeles group is invalid, but this, of course, does not make the basic findings shown in Table 5 go away. Preliminary results from a new case-control study conducted by my department in Oxford and in London since 1980 , in contrast to our earlier findings , suggest an increased risk of breast cancer in young women who have prolonged oral contraceptive use before first pregnancyindeed the data closely resemble those published by Pike et al. in 1981. It is also known that the Centers for Disease Control study, which now includes over 4000 women with breast cancer, is essentially entirely negative although the data have not been published and cannot, therefore, be subjected to proper scientific scrutiny. The situation is, therefore, extremely confused and it may be some years yet before a conclusive answer about the possible effects of early pill use on breast cancer risk becomes available. Unfortunately, the large cohort studies are unlikely to be of much assistance in settling this matter as they include few women with extensive oral contraceptive use at a young age.
Cancer of the cervix uteri Studies attempting to relate the risk of neoplasia of the cervix uteri to the use of oral contraceptives are beset by many difficulties (Swan & Pettiti 1982) . First, it is extremely difficult to make adequate allowance for the effect of confounding variablesespecially age at first sexual intercourse and number of sexual partners, which are powerful predictors of cervical neoplasia risk. Secondly, it is reasonably well established that occlusive methods of contraception offer some protection against cervical neoplasia. Thirdly, since almost all preinvasive lesions and many invasive ones are detected by cervical cytology, any substantial difference in the pattern of smear examinations between groups being compared may easily lead to incorrect conclusions. Fourthly, histopathologists vary greatly in their interpretation and classification of preinvasive lesions of the cervix, and this can lead to serious bias if any one pathologist receives a disproportionate amount of material from women using a particular contraceptive method.
Perhaps not surprisingly, almost all published studies of the possible relationship between oral contraceptive use and cancer of the cervix deal with the preinvasive lesions, dysplasia or carcinoma-in-situ (cervical intraepithelial neoplasia). Many investigations have been based on data derived from routine cervical cytology screening programmes; such studies are difficult to interpret and have yielded conflicting results. Most of the remaining studies (which have dealt with histologically diagnosed lesions) have been well reviewed by a World Health Organization Scientific Group (1978) . Of the case-control studies, those by Worth & Boyes (1972) , Thomas (1972) and Boyce et al. (1977) indicated no relation, while those by Ory et al. (1977) and Harris et al. (1980) showed a positive association between risk and duration of use. Cohort studies of cervical neoplasia and the pill have tended to produce positive results. Thus in the Walnut Creek study a statistically significant association between the incidence of carcinoma-in-situ and duration of pill use was reported (Peritz et al. 1977) , although it was subsequently suggested that this result was to some extent attributable to confounding by differences in sexual activity, both between users and nonusers of oral contraceptives and among women with different durations of oral contraceptive use (Swan & Brown 1981) . Again, in a large cohort study conducted in Los Angeles, rates of progession from cervical dysplasia to carcinoma-in-situ were much higher in women using Ovulen than in women using intrauterine devices (Stern et al. 1977) .
The most recent cohort data come from the Oxford-Family Planning Association contraceptive study (Vessey et al. 1983b, c) . In this analysis, the incidence of biopsy-proven cervical neoplasia during a 10-year follow-up period was determined in 6838 parous women who entered the study while using oral contraceptives and 3154 parous women who entered the study while using an intrauterine device (IUD). Risk factors for cervical neoplasia, and frequency of examination by cervical cytology, were similar in the two groups. All 13 cases of invasive cancer occurred in women in the oral contraceptive group; 9 had more than 6 years' use of the pill. Both carcinoma-in-situ and dysplasia also occurred more frequently in the oral contraceptive group than in the IUD group and, when the two conditions were considered together, there was a trend in incidence with duration of oral contraceptive use. The incidence of all three forms of neoplasia combined rose from 0.9 per 1000 woman-years in those with up to 2 years' pill use to 2.2 per 1000 woman-years in those with more than 8 years' pill use. Amongst the IUD users there was no such trend in incidence with duration of use; the rate fluctuated around 1.0 per 1000 woman-years. It is known that a large World Health Organization study of oral contraceptives and invasive cervical cancer has recently been completed. The results are eagerly awaited.
Other tumours
There is little doubt that hepatocellular adenomas occur much more frequently in oral contraceptive users than in other women, although their incidence among the former is still extremely low (perhaps 1-2 per 100000 users per annum). Evidence in support of this association has been derived from numerous case reports and (more importantly) from two case-control studies (Edmondson et al. 1976 , Rooks et al. 1979 . The risk seems to be greatest in older women using oral contraceptives of high hormonal potency over a long period of time (Rooks et al. 1979) . The suspicion that oral contraceptive use may also, on very rare occasions, lead to the occurrence of hepatocellular carcinoma is supported by the findings in a recent case-control study from Los Angeles (Henderson et al. 1983b) .
The possibility that oral contraceptive use might increase the risk of malignant melanoma of the skin was first raised by Beral et al. in 1977 on the basis of data collected in the Walnut Creek area in California. Subsequent studies have given conflicting results (Adam et al. 1981 , Bain et al. 1982 , Holly et al. 1983 ). However, no investigation has yet been reported which includes a sufficiently large number of cases with long-term oral contraceptive use for any firm conclusions to be drawn. For many years it has been widely held that oral contraceptive use increases the risk of certain benign tumours of the pituitary gland, particularly prolactinoma. Two recently reported case-control studies have provided strong evidence against this association (Shy et al. 1983 , Pituitary Adenoma Study Group 1983 . Shy et al. (1983) have suggested that previous reports of an association between pill use and prolactinoma may have resulted from oral contraceptive treatment of menstrual irregularity in women with an undiagnosed tumour.
Comment
Further research into the effects of oral contraceptive use on cancer is obviously of great importance. It should focus on defining the risks and benefits according to patterns of use and types of preparation. Clearly, the long-term aim must be to develop a pill or pills which will retain the known benefits of existing preparations, but not be associated with serious hazards. A major handicap at present for epidemiologists working in this field is the absence of useful information from the laboratory and from clinical research about the ways in which different oral contraceptives might be grouped together when attempting to assess their effects on certain end organs, particularly the breast. Perhaps the attempt by Pike et al. (1983) to stimulate interest in this kind of approach, while having unfortunate immediate consequences, will encourage appropriate basic research in the immediate future.
